Letter to the Editor
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 28, 2022; 28(16): 1718-1721
Published online Apr 28, 2022. doi: 10.3748/wjg.v28.i16.1718
Viral hepatitis: A global burden needs future directions for the management
Henu Kumar Verma, Kiran Prasad, Pramod Kumar, Bhaskar Lvks
Henu Kumar Verma, Department of Immunopathology, Institute of Lungs Biology and Disease, Comprehensive Pneumology Center, Helmholtz Zentrum, Munich 80331, Bayren, Germany
Kiran Prasad, Bhaskar Lvks, Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495001, Chhattisgarh, India
Pramod Kumar, Department of Drug Delivery, Institute of Lung Biology and Disease, Helmholtz Research Center, Munich 80331, Bayren, Germany
Author contributions: Verma HK, Prasad K, Kumar P and Lvks B wrote and revised the letter.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Henu Kumar Verma, PhD, Research Scientist, Senior Researcher, Department of Immunopathology, Institute of Lungs Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, 85764 Neuherberg, Munich 80331, Bayren, Germany. henu.verma@yahoo.com
Received: August 29, 2021
Peer-review started: August 29, 2021
First decision: September 29, 2021
Revised: October 9, 2021
Accepted: March 25, 2022
Article in press: March 25, 2022
Published online: April 28, 2022
Processing time: 237 Days and 22.6 Hours
Core Tip

Core Tip: Vaccination is the primary strategy for neutralizing several hepatitis viruses and it is highly effective against most hepatitis viruses. However, additional precautions must be taken for patients at a higher risk of infection such as those who take drugs, prisoners, the homeless or homosexuals. From interferon monotherapy and interferon combination therapy with direct-acting antiviral agents to interferon-free regimens which act by viral chain braking are among the measures to control hepatitis. These strategies can play a critical role in achieving World Health Organization's an ambitious but attainable goal of eliminating hepatitis infection by 2030.